This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.
Everyone wants the best treatment available when it comes to cancer, breast cancer is no different. This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy. Avastin is still available for other types of cancer but because it is no longer approved for breast cancer insurance companies will not cover the approximately $8000.00 per month it costs. This puts breast cancer treatment out of reach for many women who say this was working for them.
Gender discrepancy found in ABCA4-associated retinopathy
April 18th 2024A recent meta-analysis suggests sex as a modifying factor in the development of ABCA4-associated retinopathy, revealing a higher proportion of women among individuals with a mild reduced penetrant ABCA4 variant, impacting prognosis predictions and recurrence risks.
Read More